Use of F-18 Fluorodeoxyglucose Positron Emission Tomography With Dual-Phase Imaging to Identify Intraductal Papillary Mucinous Neoplasm
BACKGROUND & AIMS: We investigated the usefulness of dual-phase, F-18 fluorodeoxyglucose positron emission tomography with computed tomography (FDGPET/CT) to differentiate benign from malignant intraductal papillary mucinous neoplasms (IPMNs) and evaluate branch-duct IPMNs. METHODS: We used FDG-PET/CT to evaluate IPMNs in 48 consecutive patients, from May 2004 to March 2012, who underwent surgical resection. IPMNs were classified as benign (n=16) or malignant (n=32) based on histology analysis. The ability of FDG-PET/CT to identify branch-duct IPMNs was compared with that of the International Consensus Guidelines. RESULTS: The maximum standardized uptake value (SUV(max)) was higher for early-phase malignant IPMNs than that for benign IPMNs (3.5±2.2 vs 1.5±0.4;P <.001). When the SUV(max) cut-off value was set at 2.0, early-phase malignant IPMNs were identified with 88% sensitivity, specificity, and accuracy. The retention index (RI) values for malignant and benign IPMNs were 19.6±17.8 and -2.6±12.9, respectively. When the SUV(max) cut-off was set to 2.0 and the RI value to -10.0, early-phase malignant IPMNs were identified with 88% sensitivity, 94% specificity, and 90%, accuracy. In identification of branch-duct IPMNs, when the SUV(max) cut-off was set to 2.0, the sensitivity, specificity, and accuracy values were 79%, 92%, and 84%, respectively. Using a maximum main pancreatic duct diameter =7 mm, the Guidelines identified branch-duct IPMNs with greater specificity than FDG-PET/CT. The Guideline criteria of maximum cyst size =30 mm and the presence of intramural nodules identified branch-duct IPMNs with almost equal sensitivity to FDGPET/CT. CONCLUSIONS: Dual-phase FDG-PET/CT is useful for preoperative identification of malignant IPMN and for evaluating branch-duct IPMN.
Available from: Jinhwa Hong
- "However, many different acquisition protocols have been proposed to overcome the aforementioned false-negative or false-positive results obtained with 18F-FDG-PET/CT. Saito et al.
 used a protocol involving early-phase and delayed-phase scans (1 h and 2 h after 18F-FDG administration) in 48 consecutive patients with intraductal papillary mucinous neoplasia of the pancreas. In this study, SUVmax increased further in the delayed phase imaging in 92.3% patients with malignant pancreatic neoplasia, and only 60.0% of those with benign pancreatic neoplasia. "
[Show abstract] [Hide abstract]
ABSTRACT: The aim of our study is to establish the potential role of dual-phase 18F-fluorodeoxyglucose positron emission tomography / computed tomography (FDG-PET/CT) in patients presenting ovarian masses with diffuse peritoneal infiltration for differentiating benign from malignant lesions.
Twenty patients (13 with ovarian cancers and 7 with benign lesions) were evaluated preoperatively by dual-phase 18F-FDG-PET/CT performed 1 h and 2 h after injection of 18F-FDG. The maximum standardized uptake value (SUVmax) for both time points SUVmax1 and SUVmax2 were determined, respectively, and the retention index (RI) was calculated by subtracting the SUVmax1 from the SUVmax2 and dividing by SUVmax1.
The areas under the receiver operating characteristic curves (AUCs) of SUVmax1 and SUVmax2 were 0.753 (P = 0.062, 95 % confidence interval [CI] = 0.512-0.915) and 0.835 (P = 0.001, 95 % CI = 0.604-0.961), respectively. The AUC of the RI was 0.901 (P < 0.001, 95 % CI = 0.684-0.988). Using pairwise comparisons, the AUC of SUVmax2 was significantly higher than that of SUVmax1 (P = 0.032). The AUC of the RI was higher than those of SUVmax1 and SUVmax2, but the difference was not statistically significant.
Dual-phase 18F-FDG PET/CT might be considered when preoperative imaging is indeterminate. A larger-scaled, prospective study is needed to verify these results.
Journal of Ovarian Research 02/2014; 7(1):15. DOI:10.1186/1757-2215-7-15 · 2.43 Impact Factor
Available from: Punit Sharma
ECAB Clinical Update: Gastroenterology/Hepatology, Edited by Pramod Garg, 09/2013: pages 1-19; Elsevier., ISBN: 978-81-312-3486-0
Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 11/2013; 12(3). DOI:10.1016/j.cgh.2013.11.008 · 7.90 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.